Search results
Results from the WOW.Com Content Network
Like Meniere's Disease, a low salt diet is recommended as a preventative measure. A diuretic may be prescribed to help lower salt content. [13] Betahistine is the most widely prescribed medication for the treatment of Meniere's disease. The drug is thought to increase blood flow to the inner ear and to prevent the frequency and intensity of ...
List of Antiviral Drugs Antiviral Use Manufacturer Component Type Year approved Abacavir: HIV: ViiV Healthcare: Nucleoside analogue reverse transcriptase inhibitor (NRTI) 1998 Acyclovir (Aciclovir) Herpes Simplex, chickenpox, [2] varicella zoster virus: GSK: guanosine analogue RTI 1981 Adefovir: Hepatitis B [3] Gilead Sciences RTI 2002 , 2003 ...
[4] [19] For longer-term treatment to stop progression, the evidence base is weak for all treatments. [4] Although a causal relation between allergy and Ménière's disease is uncertain, medication to control allergies may be helpful. [20]
Even when physicians diagnose older patients with influenza, use of antiviral treatment can be low. [67] Provider knowledge of antiviral therapies can improve patient care, especially in geriatric medicine. Furthermore, in local health departments (LHDs) with access to antivirals, guidelines may be unclear, causing delays in treatment. [68]
Betahistine, sold under the brand name Serc among others, is an anti-vertigo medication.It is commonly prescribed for balance disorders or to alleviate vertigo symptoms.It was first registered in Europe in 1970 for the treatment of Ménière's disease, but current evidence does not support its efficacy in treating it.
Neuraminidase inhibitors (NAIs) are a class of drugs which block the neuraminidase enzyme. They are a commonly used antiviral drug type against influenza. Viral neuraminidases are essential for influenza reproduction, facilitating viral budding from the host cell.
BSAs are potential candidates for treatment of emerging and re-emerging viruses, such as ebola, marburg, and SARS-CoV-2. [3] [4] Many BSAs show antiviral activity against other viruses than originally investigated (such as remdesivir and interferon alfa). Efforts in drug repurposing for SARS-CoV-2 is currently underway.
The two studies had a total of 2096 participants and more than 90% (1945) completed the trial. The most common reason for a participant not finishing the trial was an adverse event. Pleconaril treatment showed a reduction in nose blowing, sleep disturbance, and less cold medication used. [14]